SkinBioTherapeutics (SBTX.L) Stock Price
SkinBioTherapeutics Price
Revenue has compounded at 295.8% per year over the past 3 years to 4.64 M GBP. SkinBioTherapeutics's net margin stands at -15.0%, up from -3,733.4% several years earlier. Analysts set a median price target of 29.58 GBP, implying 32,675.6% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 74% above its 52-week low.
SkinBioTherapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of SkinBioTherapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how SkinBioTherapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing SkinBioTherapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | SkinBioTherapeutics Price |
|---|---|
| 9/16/2026 | 0.09 GBP |
| 9/15/2026 | 0.09 GBP |
| 9/14/2026 | 0.10 GBP |
| 9/11/2026 | 0.09 GBP |
| 9/10/2026 | 0.09 GBP |
| 9/9/2026 | 0.10 GBP |
| 9/8/2026 | 0.10 GBP |
| 9/7/2026 | 0.10 GBP |
| 9/4/2026 | 0.10 GBP |
| 9/3/2026 | 0.10 GBP |
| 9/2/2026 | 0.09 GBP |
| 9/1/2026 | 0.10 GBP |
| 8/28/2026 | 0.09 GBP |
| 8/27/2026 | 0.10 GBP |
| 8/26/2026 | 0.10 GBP |
| 8/24/2026 | 0.09 GBP |
| 8/21/2026 | 0.10 GBP |
| 8/20/2026 | 0.10 GBP |
| 8/19/2026 | 0.10 GBP |
| 8/18/2026 | 0.10 GBP |
| 8/17/2026 | 0.10 GBP |
| 8/14/2026 | 0.10 GBP |
| 8/13/2026 | 0.10 GBP |
| 8/12/2026 | 0.11 GBP |
| 8/11/2026 | 0.11 GBP |
| 8/10/2026 | 0.11 GBP |
| 8/7/2026 | 0.11 GBP |
| 8/6/2026 | 0.11 GBP |
| 8/5/2026 | 0.11 GBP |
| 8/4/2026 | 0.11 GBP |
SkinBioTherapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
SkinBioTherapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM GBP |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM GBP |
| EBITM GBP |
| EBIT MARGIN% |
| NET INCOMEM GBP |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | 1.00 | 4.00 | 6.00 | 8.00 |
| – | – | – | – | – | – | – | – | – | 300.00 | 50.00 | 33.33 |
| – | – | – | – | – | – | – | – | 200.00 | 50.00 | 50.00 | 50.00 |
| 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 4.00 |
| – | – | – | -1.00 | -1.00 | -1.00 | -2.00 | -2.00 | -2.00 | -1.00 | -2.00 | -3.00 |
| – | – | – | – | – | – | – | – | -200.00 | -25.00 | -33.33 | -37.50 |
| – | – | – | -1.00 | -1.00 | -1.00 | -2.00 | -2.00 | -2.00 | – | – | – |
| – | – | – | – | – | – | 100.00 | – | – | – | – | – |
| 119.02 | 119.02 | 119.02 | 122.37 | 128.42 | 146.70 | 156.78 | 164.71 | 186.29 | 227.87 | 227.87 | 227.87 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales SkinBioTherapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue SkinBioTherapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare SkinBioTherapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares SkinBioTherapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against SkinBioTherapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
SkinBioTherapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
SkinBioTherapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
SkinBioTherapeutics business model & stock analysis
SkinBioTherapeutics SWOT Analysis
Strengths
SkinBioTherapeutics PLC has several strengths that contribute to its success in the market:
- Unique Biotechnology: SkinBioTherapeutics utilizes innovative biotechnology to develop and produce cutting-edge skincare products.
- Scientific Expertise: The company benefits from a team of highly skilled scientists and researchers who bring invaluable knowledge and experience to their product development.
- Clinical Validation: SkinBioTherapeutics has successfully conducted clinical trials that demonstrate the efficacy and safety of their products, giving them a competitive advantage in the market.
- Strong Industry Partnerships: The company has established strategic partnerships with key players in the skincare and pharmaceutical industries, enabling access to distribution channels and potential collaborative opportunities.
Weaknesses
While SkinBioTherapeutics PLC has several strengths, there are also a few weaknesses that should be addressed:
- Limited Product Portfolio: The company currently has a limited range of skincare products in its portfolio, which may restrict its market reach and revenue potential.
- Dependency on External Funding: SkinBioTherapeutics relies heavily on external funding sources, such as grants and partnerships, to support its research and development activities.
- Market Volatility: The skincare industry is highly competitive and subject to rapidly changing consumer preferences, posing a challenge to SkinBioTherapeutics' ability to stay ahead of market trends.
Opportunities
There are several opportunities that SkinBioTherapeutics PLC can explore to further grow and expand its business:
- Increasing Demand for Natural Products: With the rising trend of consumers seeking natural and organic skincare solutions, SkinBioTherapeutics can leverage its biotechnology expertise to develop innovative natural products.
- International Expansion: Expanding into new markets globally can provide SkinBioTherapeutics with access to a larger customer base and increased revenue streams.
- Partnership Opportunities: The company can explore collaborative partnerships with established skincare brands or pharmaceutical companies to accelerate product development and enhance market penetration.
Threats
SkinBioTherapeutics PLC should also be aware of potential threats that could impact its business:
- Competitive Landscape: The skincare industry is highly competitive, with numerous established brands and emerging players vying for market share. SkinBioTherapeutics needs to continuously innovate to stay ahead of the competition.
- Regulatory Challenges: The company must navigate stringent regulations and compliance requirements related to product development and marketing in the skincare industry.
- Market Disruptions: External factors such as economic downturns or unforeseen events can disrupt consumer spending patterns and affect overall demand for skincare products.
SkinBioTherapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
SkinBioTherapeutics historical P/E ratio, EBIT multiple, and P/S ratio
SkinBioTherapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down SkinBioTherapeutics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in SkinBioTherapeutics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare SkinBioTherapeutics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
SkinBioTherapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current SkinBioTherapeutics forecasts and price targets in September 2026
Analyst Price Targets 2026SkinBioTherapeutics shareholder structure
| % | Name |
|---|---|
23.25919% | |
7.20456% | |
7.12489% | |
6.40725% | |
4.63490% | |
3.46463% |
SkinBioTherapeutics Executives and Management Board
5 members · avg. age 47 · 40 % women
Mr. Stuart Ashman
Chief Executive Officer, Executive Director · since 2019
324,642.00 GBP
Management
Mr. Simon Hewitson
Chief Operating Officer, Executive Director · since 2025
Board of Directors
Mr. Martin Hunt
Non-Executive Independent Chairman of the Board
Dr. Catherine Prescott
Non-Executive Independent Director
Ms. Danielle Bekker (47)
Non-Executive Independent Director
Frequently asked questions about SkinBioTherapeutics
The business model of SkinBioTherapeutics PLC focuses on the research, development, and commercialization of microbiome-based skincare products. By leveraging the potential of the skin's microbiome, the company aims to innovate and deliver scientifically proven skin health solutions. SkinBioTherapeutics PLC utilizes its proprietary SkinBiotix technology to develop and formulate microbiome-targeted products that have the potential to improve various skin conditions. With a strong emphasis on scientific research and collaboration, the company aims to address the growing demand for solutions that promote healthy skin. Through strategic partnerships and continuous innovation, SkinBioTherapeutics PLC aims to establish itself as a leader in the microbiome-based skincare industry.
SkinBioTherapeutics PLC primarily operates in the healthcare and pharmaceutical industries.
The main competitors of SkinBioTherapeutics PLC in the market are companies like Procter & Gamble Co., Unilever PLC, L'Oréal SA, Johnson & Johnson, and Estée Lauder Companies Inc. These companies also operate in the skincare and dermatology industry, offering a range of products and services that may compete with SkinBioTherapeutics PLC.
SkinBioTherapeutics PLC is a renowned company specializing in the development of innovative products for the cosmetic and healthcare industries. Established in 2016, SkinBioTherapeutics PLC has quickly gained recognition for its cutting-edge research and commitment to improving skin health. The company focuses on harnessing the skin's natural biofilms to develop groundbreaking solutions for conditions like acne, psoriasis, and aging skin. With a team of expert scientists and researchers, SkinBioTherapeutics PLC has made significant strides in understanding the skin microbiome and its impact on overall skin health. The company's dedication to scientific excellence and customer satisfaction has solidified its position as a leader in the industry.
SkinBioTherapeutics PLC has achieved several significant milestones. These include successful completion of its Phase I clinical trial for its flagship product, SkinBiotix®, which demonstrated excellent safety and tolerability. Additionally, the company has entered into various strategic collaborations with renowned industry partners, such as Croda International PLC, to enhance the development and commercialization of its products. SkinBioTherapeutics has also gained recognition through numerous awards and grants, emphasizing its commitment to innovation and excellence in skincare solutions. As a leading skincare company, SkinBioTherapeutics PLC continues to make remarkable strides in advancing the field of microbiome-based therapeutics for healthier and rejuvenated skin.
SkinBioTherapeutics PLC is primarily present in the United Kingdom.
SkinBioTherapeutics PLC represents values of innovation, scientific excellence, and commitment to improving skin health. The company focuses on developing unique microbiome-based treatments that address various skin conditions. Its corporate philosophy revolves around leveraging cutting-edge research and technology to deliver safe and effective solutions for dermatological needs. SkinBioTherapeutics PLC aims to provide individuals with quality products that enhance skin wellness and restore confidence. By continuously exploring the potential of the skin microbiome, the company aims to transform the field of skincare and contribute to a healthier future for all.
Analysts currently set an average price target of 29.58 GBP for the SkinBioTherapeutics stock (median: 29.58 GBP), implying +228.7 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the SkinBioTherapeutics stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SkinBioTherapeutics to generate revenue of 6.20 M GBP and earnings per share of -0.00 GBP.
Converted at the current exchange rate, the SkinBioTherapeutics share trades at 0.11 EUR (0.09 GBP).
The SkinBioTherapeutics share (SBTX.L) is listed on 3 stock exchanges, including: London (SBTX.L), Frankfurt (5KW.F).
The SkinBioTherapeutics PLC is a company specializing in biotech products for skincare. Its business model is based on the development of products that are based on probiotics and other natural ingredients and treat and prevent skin conditions. The company operates in three main divisions: research and development, manufacturing, and distribution. In the research department, new products are developed targeting specific dermatoses. The company has focused its research on probiotics and develops products based on the microorganisms on the skin. Manufacturing takes place in specially equipped laboratories to ensure strict quality standards. SkinBioTherapeutics' flagship product is the SkinBiotix program. This consists of a range of products based on the skin's flora and developed to treat various skin conditions. The program offers solutions for skin conditions such as acne, eczema, and rosacea. The company also has a partnership with Winclove Probiotics to develop a product called AxisBiotix. This product is intended to support microbial diversity in the gut, which can have a positive effect on the skin. The idea behind this is that many skin problems are related to impaired gut function. SkinBioTherapeutics also has the potential to operate in the dermocosmetics sector. The company can bring its products to the cosmetic market based on its research and development of probiotic products. The brand "Synbiotix" has already been introduced and is intended to offer a wider range of skincare products. The company also plans to make its technology platform, SkinBiotix, available to other companies through licensing agreements. The technology is innovative and unique and has the potential to change the way we look at skincare products. SkinBioTherapeutics positions itself as a company that sets itself apart from other skincare companies by being based on microbiology and science rather than fashion trends or pseudoscience. The company emphasizes the scientific approach and the fact that its products are based on the skin's flora, which means they are more natural and effective. SkinBioTherapeutics' business model is based on innovative research and development and the use of probiotics in skincare products. The company offers a wide range of products based on the SkinBiotix technology targeting a variety of skin conditions. The company also plans to make its technology platform available to other companies and expand its presence in the cosmetic market.
The expected revenue of SkinBioTherapeutics is 6.20 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SkinBioTherapeutics is -4,557.34 GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SkinBioTherapeutics is currently -4,512.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SkinBioTherapeutics stock.
The price-to-sales ratio (P/S) of SkinBioTherapeutics is currently 3.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SkinBioTherapeutics stock.
The Eulerpool Quality Score for SkinBioTherapeutics is 3/10.
The ISIN of SkinBioTherapeutics is GB00BF33H870. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of SkinBioTherapeutics is A2DPW8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of SkinBioTherapeutics is SBTX.L. The ticker symbol is used to trade SkinBioTherapeutics shares on the stock exchange.
SkinBioTherapeutics paid dividends every year for the past 0 years.
SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.
The dividends of SkinBioTherapeutics are distributed in GBP.
SkinBioTherapeutics stock
SkinBioTherapeutics Peer Group
SkinBioTherapeutics Ticker
SkinBioTherapeutics FIGI
All fundamentals and in-depth analysis of SkinBioTherapeutics
Our stock analysis for SkinBioTherapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SkinBioTherapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.